Diabetes Treatment and Management
Moving in Annals of Internal Medicine.
- Moved, week to 23 Oct 2026
- 1
- Papers in 60 days
- 23
Rebuilt
Moved this week
Latest in Diabetes Treatment and Management
Newest first · last 60 days
Retatrutide significantly reduces the apnea-hypopnea index by up to 34.3 events per hour in adults with moderate-to-severe obstructive sleep apnea and obesity.
Diabetes diagnosis causes a temporary 13 percentage point increase in diagnosis rates and reduces labor-force participation by 20.6 percentage points in the two years following screening.
- Open access
Digital delivery of GLP-1RA therapy in women results in a mean weight loss of 16.1 kg, or 15.5% of baseline weight, in a real-world UK cohort.
- Open access
Continuous glucose monitoring reduces glycated hemoglobin levels by 0.9 percentage points in adults with non-insulin-treated type 2 diabetes over 26 weeks.
A scalable 3D β-cell spheroid platform enables real-time measurement of Ca(2+) oscillations and insulin release in response to glucose and modulators.
- Open access
Safiglipron at all tested doses is non-inferior to dapagliflozin in reducing HbA1c in adults with type 2 diabetes over 32 weeks.
- Open access
DD01 achieved a 76% rate of at least 30% liver fat reduction at 12 weeks in adults with MASLD or MASH, significantly surpassing the 12% in the placebo group.
Semaglutide reduces vascular resistance and prevents fibrosis in kidneys of people with type 2 diabetes and chronic kidney disease, as shown by secondary outcomes.
- Open access
Multidisciplinary heart-liver co-management improves detection and treatment of MASLD, addressing a critical gap in cardiometabolic care with potential to reduce mortality.
Robust real-world evidence is essential to optimize GLP-1 receptor agonist use and inform policy decisions amid expanding indications and diverse populations.
- Open access
- 1 cites
Methodological approaches like pragmatic clinical trials and target trial emulation are emphasized as strategies to improve real-world evidence for GLP-1 receptor agonists.
- 1 cites
Glucagon-like peptide-1 receptor agonists increase the 18-month risk of ischemic optic neuropathy by approximately 3 to 3.6 cases per 10,000 patients compared to other diabetes medications.
Use of GLP-1 receptor agonists is associated with a nearly twofold increased risk of anterior ischemic optic neuropathy in type 2 diabetes patients, but absolute risk remains small.
Effective obesity treatments, including new medications and procedures, are available but have not significantly reduced obesity rates in the US, which remain stable.
Add Diabetes Treatment and Management as an interest in JClub
Browse JClub
Journals this month
- bioRxiv6131
- medRxiv1703
- PNAS447
- Sci Adv354
- JAMA262
- Environ Res230
- BMJ182
- Environ Pollution165
- Nat Commun161
- Science141
- Nature138
- Lancet128
- Cell Rep120
- NEJM119
- mBio107
- Plant Cell Environ107
- Curr Biol106
- J Exp Bot106
Topics moving, week to 23 Oct 2026
- Single-cell and spatial transcriptomics6
- Neuroinflammation and Neurodegeneration Mechanisms5
- Bacteriophages and microbial interactions5
- Gut microbiota and health5
- Genomics and Phylogenetic Studies4
- Cancer Genomics and Diagnostics4
- Cancer Immunotherapy and Biomarkers4
- Alzheimer's disease research and treatments3
- Inflammatory Bowel Disease3
- Influenza Virus Research Studies3